Erratum: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors

Manish R. Sharma

START Center for Cancer Research—Midwest, Grand Rapids, MI

John Powderly

Carolina BioOncology Institute, Huntersville, NC

Yasutoshi Kuboki

Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan

John H. Strickler

Ruth Perets

Rambam Medical Center and Technion-Israel Institute of Technology, Haifa, Israel

Jonathan E. Cohen

Hadassah Hebrew University Medical Center, Jerusalem, Israel

Judith Raimboaurg

Takako Eguchi Nakajima

Noboru Yamamoto

Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo

Marcia Cruz-Correa

The University of Puerto Rico, Medical Sciences Campus, and Pan-American Center for Oncology Trials, San Juan, Puerto Rico

Bert O'Neil

Oncology, Community Health Network North Cancer Center, Indianapolis, IN

François Ghiringhelli

Kanwal Raghav

Michael Cecchini

Yale University School of Medicine, New Haven, CT

Jair Bar

Institute of Oncology Chaim Sheba Medical Center Ramat Gan Israel

Zoë Hunter

AbbVie Inc, North Chicago, IL

Michael Burns

AbbVie Inc, North Chicago, IL

Martha Blaney

AbbVie Inc, North Chicago, IL

Gladys Morrison-Thiele

AbbVie Inc, North Chicago, IL

Martha Neagu Aristide

AbbVie Inc, North Chicago, IL

Kevin J. Freise

AbbVie Inc, North Chicago, IL

Rui Li

Martha Li

AbbVie Inc, North Chicago, IL

Athan Vasilopoulos

AbbVie Inc, North Chicago, IL

Carla Biesdorf

AbbVie Inc, North Chicago, IL

David Sommerhalder

NEXT Oncology, San Antonio, TX